Literature DB >> 25204821

Development of nanoparticles for clinical use.

Tore Skotland1, Tore-Geir Iversen, Kirsten Sandvig.   

Abstract

Keywords:  drug approval; excretion; metabolism; nanoparticles; risk/benefit; toxicity

Mesh：

Substances：

Year:  2014        PMID： 25204821     DOI： 10.2217/nnm.14.81

Source DB:  PubMed          Journal:  Nanomedicine (Lond)        ISSN： 1743-5889            Impact factor:   5.307


× No keyword cloud information.
  5 in total

1.  Remotely Triggered Nano-Theranostics For Cancer Applications.

Authors:  Alexandra Sneider; Derek VanDyke; Shailee Paliwal; Prakash Rai
Journal:  Nanotheranostics       Date:  2017

Review 2.  Intracellular Transport and Cytotoxicity of the Protein Toxin Ricin.

Authors:  Natalia Sowa-Rogozińska; Hanna Sominka; Jowita Nowakowska-Gołacka; Kirsten Sandvig; Monika Słomińska-Wojewódzka
Journal:  Toxins (Basel)       Date:  2019-06-18       Impact factor: 4.546

3.  Cellular uptake and intracellular degradation of poly(alkyl cyanoacrylate) nanoparticles.

Authors:  Einar Sulheim; Habib Baghirov; Eva von Haartman; Andreas Bøe; Andreas K O Åslund; Yrr Mørch; Catharina de Lange Davies
Journal:  J Nanobiotechnology       Date:  2016-01-08       Impact factor: 10.435

4.  Paclitaxel-loaded biodegradable ROS-sensitive nanoparticles for cancer therapy.

Authors:  Abhilash D Pandya; Eliézer Jäger; Shahla Bagheri Fam; Anita Höcherl; Alessandro Jäger; Vladimir Sincari; Bo Nyström; Petr Štěpánek; Tore Skotland; Kirsten Sandvig; Martin Hrubý; Gunhild M Mælandsmo
Journal:  Int J Nanomedicine       Date:  2019-08-06

5.  Biological response and cytotoxicity induced by lipid nanocapsules.

Authors:  Marzena Szwed; Maria Lyngaas Torgersen; Remya Valsala Kumari; Sunil Kumar Yadava; Sascha Pust; Tore Geir Iversen; Tore Skotland; Jyotsnendu Giri; Kirsten Sandvig
Journal:  J Nanobiotechnology       Date:  2020-01-06       Impact factor: 10.435
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.